Assembly Biosciences. has filed a patent for pyrazole carboxamide compounds that can disrupt HBV core protein assembly and potentially treat Hepatitis B infection. The compounds and their pharmaceutical compositions are described in the patent claim. GlobalData’s report on Assembly Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Assembly Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Assembly Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Assembly Biosciences's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for pyrazole carboxamide compounds for treating hepatitis b

Source: United States Patent and Trademark Office (USPTO). Credit: Assembly Biosciences Inc

A recently filed patent (Publication Number: US20230295096A1) describes a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound has various substituents and functional groups, including L, L1, X3, X4, X5, Ra, Rb, Rc, Rd, Rx1, R0a, R4a, R6b, R0, R6, R11, R1, R2, R8, R3a, R4, R5, R9, R14, q, r, t, w, and v. These substituents and functional groups can be independently selected from a range of options, such as hydrogen, alkyl groups, halogen groups, and heteroaryl groups. The compound can be used in the treatment of Hepatitis B (HBV) infection.

In claim 1, the compound of Formula I or a pharmaceutically acceptable salt thereof is described, along with the various substituents and functional groups that can be present. Claim 2 specifies that Rx1 can be hydrogen or methyl, while claim 3 narrows it down to methyl. Claim 4 states that r can be 0, and claim 5 specifies that R2 can be RaRbN. Claim 6 further narrows down R2 to NH2. Claim 7 describes R1, R11, and z1, with various options for R11 and z1. Claim 8 specifies that R11 can be CN, F, Cl, Br, or I. Claim 9 does not provide any specific information about R1. Claim 10 states that X3 can be CR4R8. Claim 11 and claim 12 describe the relationship between R4 and R9, and R4 and R5-L1, respectively. Claim 13 specifies that L1 can be a bond. Claim 14, claim 15, and claim 16 provide options for R8, including hydrogen, OH, and C1-6 alkoxy. Claim 17 describes a pharmaceutical composition comprising the compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. Claim 18 and claim 19 outline methods of treating Hepatitis B (HBV) infection using the compound or the pharmaceutical composition, respectively.

Overall, this patent describes a compound and its various substituents and functional groups, along with its potential use in the treatment of Hepatitis B (HBV) infection. The claims provide specific options and variations for these substituents and functional groups, allowing for potential customization and optimization of the compound for therapeutic purposes.

To know more about GlobalData’s detailed insights on Assembly Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies